Comprehensive Medical Weight Loss Denver
Research Brief | Dr. Ethan Lazarus, MD | Clinical Nutrition Center | October 27, 2026 A weight loss drug may also help with sleep apnea. Two large trials published in the New England Journal of Medicine on October 21, 2026…
Research Brief — Dr. Ethan Lazarus, MD, DABOM, DABFM, MFOMA | Clinical Nutrition Center | October 9, 2026 At EASD 2026 in Milan, Eli Lilly dropped Phase 2b data on EloraTZP — a combination of eloralintide (a selective amylin receptor…
Published: September 13, 2026 | Category: Drug Approval On September 11, 2026, the FDA approved Isembyld (apitegromab-mstn) — the first and only therapy designed to directly target muscle tissue in spinal muscular atrophy (SMA). Developed by Scholar Rock, it represents…
A man in his early 60s came in for a cholesterol check. His LDL was 142. I recommended a statin. He declined — said he did not want to be on a maintenance drug. Six years later, his memory started…
Oral GLP-1 Pill Shows 12% Weight Loss — Colorado Trial Update A new oral obesity drug just posted Phase 2b results that deserve attention — especially here in Colorado, where we see a lot of patients who struggle with daily…
GLP-1 Medications May Reduce Alcohol Cravings — Here’s What the New Research Shows For nearly two decades, the medication cupboard for alcohol use disorder (AUD) has been mostly bare. Naltrexone has been the main option — and it helps some…
The 22.7% weight loss number doesn’t tell the whole story. CagriSema — Novo Nordisk’s combination of semaglutide plus cagrilintide, an amylin analogue — posted that figure in REDEFINE 1. It’s impressive. It’s also incomplete. Because the more interesting question isn’t…
Novo Nordisk just filed for FDA approval of CagriSema — and if the data holds, this could be the most powerful obesity medication we’ve seen yet. CagriSema combines cagrilintide, an amylin analog, with semaglutide, the GLP-1 receptor agonist in Wegovy…
Eli Lilly’s retatrutide just got more interesting. Two new Phase 3 trials—TRIUMPH-2 and TRIUMPH-3—delivered results that matter for the patients I see most: people with obesity complicated by type 2 diabetes or established cardiovascular disease. The triple GIP/GLP-1/glucagon agonist achieved…
Research Brief | Dr. Ethan Lazarus, MD | Clinical Nutrition Center | July 30, 2026 — The way American teenagers are getting treated for obesity has changed more in the last three years than in the previous three decades. A…
